Pharmaceuticals Search Engine [selected websites]

Thursday, March 29, 2012

Domain Therapeutics : EUR 933,000 grant for schizophrenia project

Domain Therapeutics
Strasbourg, France, March 13, 2012 - GPCR specialist will lead EUR 5.1 million ATHOS Project to develop new therapie -

Domain Therapeutics, a biopharmaceutical company focussed on the discovery and early development of small molecules targeting G-Protein Coupled Receptors (GPCRs), one of the most important classes of drug targets, announced that ATHOS project has been selected for French government funding. ATHOS aims to develop new drug candidates and identify therapeutic targets for schizophrenia.

Total funding will amount to EUR 5.1 million over three years. Some 45 per cent of the ATHOS budget will be provided by central and regional government organizations, including the grant of EUR 933,000 to Domain Therapeutics.

Schizophrenia is a disease of the central nervous system generally starting in adolescence and becoming a chronic condition. It typically exhibits a dissociation of the personality, giving rise to auditory hallucinations, paranoid delirium and attention disorders. These problems affect not only the patient’s mental health but also life expectancy, which is 12 years shorter than that of the general population. Schizophrenia and related conditions affect 2-3 per cent of the world population but existing treatments do not improve the cognitive disturbances resulting from the disease and some patients remain completely resistant to available treatments... 

[...]

...About Domain Therapeutics S.A. 

Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-Protein Coupled Receptors (GPCRs), one of the most important classes of drug targets. Domain Therapeutics identifies and develops drug candidates using its DTect-All (TM) innovative proprietary technology. The company’s portfolio is composed of new chemical entities ranging from hits to optimized leads for leading indications such as schizophrenia, Parkinson's disease, and diabetes... [PDF] Domain Therapeutics' Press Release -